Is myopathy a side effect of CYCLOPHOSPHAMIDE ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of CYCLOPHOSPHAMIDE patients who developed myopathy.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 51 individuals taking CYCLOPHOSPHAMIDE reported myopathy to the FDA. A total of 41352 CYCLOPHOSPHAMIDE drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between CYCLOPHOSPHAMIDE and myopathy. In doing so, we compare CYCLOPHOSPHAMIDE with other drugs that cause myopathy, to help you evaluate whether or not CYCLOPHOSPHAMIDE causes myopathy. Likewise, this page shows the most highly-reported side effects of CYCLOPHOSPHAMIDE, so you can see if myopathy ranks among CYCLOPHOSPHAMIDE's most well-known side effects.

Summary Statistics
Reports of CYCLOPHOSPHAMIDE causing myopathy: 51
Reports of any side effect of CYCLOPHOSPHAMIDE : 41352
Percentage of CYCLOPHOSPHAMIDE patients where myopathy is a reported side effect: 0.1233%

FDA reports of any drug causing myopathy : 3605
Average percentage for all medicated patients where myopathy is reported as a complication: 0.0226%

Physician opinion on CYCLOPHOSPHAMIDE as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing CYCLOPHOSPHAMIDE:

BREAST CANCER ( 4362 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 2976 patients )
NON-HODGKIN'S LYMPHOMA ( 1873 patients )
CHRONIC LYMPHOCYTIC LEUKAEMIA ( 1791 patients )
MULTIPLE MYELOMA ( 1452 patients )
B-CELL LYMPHOMA ( 1259 patients )
ACUTE LYMPHOCYTIC LEUKAEMIA ( 1145 patients )
BONE MARROW CONDITIONING REGIMEN ( 850 patients )
DRUG USE FOR UNKNOWN INDICATION ( 744 patients )
LYMPHOMA ( 676 patients )
MANTLE CELL LYMPHOMA ( 504 patients )
STEM CELL TRANSPLANT ( 484 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 484 patients )
HODGKIN'S DISEASE ( 434 patients )
BURKITT'S LYMPHOMA ( 376 patients )
CHEMOTHERAPY ( 347 patients )
T-CELL LYMPHOMA ( 273 patients )
SYSTEMIC LUPUS ERYTHEMATOSUS ( 229 patients )
WEGENER'S GRANULOMATOSIS ( 212 patients )
ACUTE MYELOID LEUKAEMIA ( 203 patients )
BREAST CANCER METASTATIC ( 203 patients )
BONE MARROW TRANSPLANT ( 201 patients )
PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED ( 181 patients )
RHABDOMYOSARCOMA ( 164 patients )
DRUG EXPOSURE DURING PREGNANCY ( 141 patients )
CORD BLOOD TRANSPLANT THERAPY ( 128 patients )
LUPUS NEPHRITIS ( 118 patients )
IMMUNOSUPPRESSION ( 93 patients )
BREAST CANCER FEMALE ( 88 patients )
MEDULLOBLASTOMA ( 86 patients )
NEUROBLASTOMA ( 81 patients )
MALIGNANT LYMPHOID NEOPLASM ( 79 patients )
WALDENSTROM'S MACROGLOBULINAEMIA ( 76 patients )
EWING'S SARCOMA ( 76 patients )
VASCULITIS ( 75 patients )
APLASTIC ANAEMIA ( 72 patients )
PROPHYLAXIS AGAINST TRANSPLANT REJECTION ( 71 patients )
NEOPLASM MALIGNANT ( 66 patients )
B PRECURSOR TYPE ACUTE LEUKAEMIA ( 66 patients )
ALLOGENIC BONE MARROW TRANSPLANTATION THERAPY ( 65 patients )
OVARIAN CANCER ( 63 patients )
ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE VASCULITIS ( 63 patients )
T-CELL TYPE ACUTE LEUKAEMIA ( 60 patients )
ADULT T-CELL LYMPHOMA/LEUKAEMIA ( 60 patients )
HAEMATOPOIETIC STEM CELL MOBILISATION ( 57 patients )
IDIOPATHIC THROMBOCYTOPENIC PURPURA ( 56 patients )
METASTATIC MALIGNANT MELANOMA ( 53 patients )
ILL-DEFINED DISORDER ( 47 patients )
LYMPHOCYTIC LEUKAEMIA ( 44 patients )
SARCOMA ( 43 patients )
RHEUMATOID ARTHRITIS ( 43 patients )
ACUTE LEUKAEMIA ( 42 patients )
MALIGNANT MELANOMA ( 40 patients )
LEUKAEMIA ( 40 patients )
PROPHYLAXIS AGAINST GRAFT VERSUS HOST DISEASE ( 39 patients )
AMYLOIDOSIS ( 37 patients )
ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT ( 34 patients )
BREAST CANCER STAGE II ( 34 patients )
MULTIPLE SCLEROSIS ( 34 patients )
EPSTEIN-BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISORDER ( 34 patients )
PREMEDICATION ( 33 patients )
CHRONIC MYELOID LEUKAEMIA ( 33 patients )
PEMPHIGUS ( 33 patients )
PRECURSOR T-LYMPHOBLASTIC LYMPHOMA/LEUKAEMIA ( 32 patients )
INTERSTITIAL LUNG DISEASE ( 32 patients )
NEPHROTIC SYNDROME ( 31 patients )
CHORIOCARCINOMA ( 31 patients )
LYMPHOPROLIFERATIVE DISORDER ( 30 patients )
NON-HODGKIN'S LYMPHOMA UNSPECIFIED HISTOLOGY AGGRESSIVE ( 29 patients )
OFF LABEL USE ( 29 patients )
B-CELL SMALL LYMPHOCYTIC LYMPHOMA ( 28 patients )
BURKITT'S LEUKAEMIA ( 28 patients )
GLOMERULONEPHRITIS ( 27 patients )
RETINOBLASTOMA ( 27 patients )
MICROSCOPIC POLYANGIITIS ( 27 patients )
PRIMITIVE NEUROECTODERMAL TUMOUR ( 27 patients )
BREAST CANCER STAGE III ( 26 patients )
GERM CELL CANCER ( 26 patients )
PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA ( 26 patients )
B-CELL TYPE ACUTE LEUKAEMIA ( 25 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 25 patients )
LYMPHOMA AIDS RELATED ( 24 patients )
CHRONIC LYMPHOCYTIC LEUKAEMIA RECURRENT ( 24 patients )
NEOPLASM ( 24 patients )
GESTATIONAL TROPHOBLASTIC TUMOUR ( 24 patients )
IMMUNOSUPPRESSANT DRUG THERAPY ( 23 patients )
RENAL TRANSPLANT ( 23 patients )
DIFFUSE LARGE B-CELL LYMPHOMA STAGE IV ( 23 patients )
EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE) ( 22 patients )
ANAEMIA HAEMOLYTIC AUTOIMMUNE ( 22 patients )
GLOMERULONEPHRITIS MEMBRANOUS ( 22 patients )
SCLERODERMA ( 22 patients )
NEPHROBLASTOMA ( 21 patients )
JUVENILE ARTHRITIS ( 21 patients )
NON-HODGKIN'S LYMPHOMA STAGE IV ( 21 patients )
ANAPLASTIC LARGE CELL LYMPHOMA T- AND NULL-CELL TYPES ( 20 patients )
PRIMARY AMYLOIDOSIS ( 20 patients )
CASTLEMAN'S DISEASE ( 20 patients )
CENTRAL NERVOUS SYSTEM LYMPHOMA ( 20 patients )
DERMATOMYOSITIS ( 20 patients )
T-CELL PROLYMPHOCYTIC LEUKAEMIA ( 19 patients )
BONE MARROW FAILURE ( 19 patients )
ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA ( 19 patients )
EPSTEIN-BARR VIRUS INFECTION ( 19 patients )
CONNECTIVE TISSUE DISORDER ( 19 patients )
MYELODYSPLASTIC SYNDROME ( 19 patients )
PROSTATE CANCER ( 18 patients )
MYCOSIS FUNGOIDES ( 18 patients )
MYELOID LEUKAEMIA ( 18 patients )
METASTASES TO LUNG ( 17 patients )
BEHCET'S SYNDROME ( 17 patients )
IDIOPATHIC PULMONARY FIBROSIS ( 17 patients )
FOLLICLE CENTRE LYMPHOMA, FOLLICULAR GRADE I, II, III STAGE IV ( 16 patients )
BONE SARCOMA ( 16 patients )
POLYARTERITIS NODOSA ( 16 patients )
BRAIN NEOPLASM MALIGNANT ( 16 patients )
AUTOLOGOUS BONE MARROW TRANSPLANTATION THERAPY ( 16 patients )
PLASMABLASTIC LYMPHOMA ( 16 patients )
HIV INFECTION ( 16 patients )
MATERNAL EXPOSURE DURING PREGNANCY ( 16 patients )
B-CELL LYMPHOMA RECURRENT ( 15 patients )
PANCREATIC CARCINOMA METASTATIC ( 15 patients )
THERAPEUTIC PROCEDURE ( 15 patients )
ACUTE MYELOID LEUKAEMIA RECURRENT ( 15 patients )
CONGENITAL APLASTIC ANAEMIA ( 15 patients )
PRIMARY EFFUSION LYMPHOMA ( 15 patients )
LYMPHOCYTIC LYMPHOMA ( 14 patients )
BREAST CANCER IN SITU ( 14 patients )
BREAST CANCER STAGE IV ( 14 patients )
UNRELATED DONOR BONE MARROW TRANSPLANTATION THERAPY ( 14 patients )
RENAL VASCULITIS ( 13 patients )
B-CELL LYMPHOMA STAGE IV ( 13 patients )
COMBINED IMMUNODEFICIENCY ( 13 patients )
PROPHYLAXIS ( 13 patients )
NON-SMALL CELL LUNG CANCER ( 13 patients )
TESTIS CANCER ( 13 patients )
GLIOBLASTOMA MULTIFORME ( 13 patients )
LEUKAEMIA RECURRENT ( 12 patients )
FOETAL EXPOSURE DURING PREGNANCY ( 12 patients )
NON-HODGKIN'S LYMPHOMA RECURRENT ( 12 patients )
TRANSPLANT ( 12 patients )
ACUTE GRAFT VERSUS HOST DISEASE ( 12 patients )
NON-HODGKIN'S LYMPHOMA STAGE III ( 11 patients )
METASTASES TO BONE ( 11 patients )
PLASMACYTOMA ( 11 patients )
ADENOCARCINOMA ( 11 patients )
GLIOMA ( 11 patients )
B-CELL LYMPHOMA STAGE III ( 11 patients )
METASTASES TO LIVER ( 11 patients )
DIFFUSE LARGE B-CELL LYMPHOMA STAGE II ( 11 patients )
GRAFT VERSUS HOST DISEASE ( 11 patients )
INFLAMMATORY CARCINOMA OF BREAST STAGE III ( 11 patients )
COLORECTAL CANCER ( 10 patients )
HEPATOSPLENIC T-CELL LYMPHOMA ( 10 patients )
POLYMYOSITIS ( 10 patients )
RICHTER'S SYNDROME ( 10 patients )
BREAST CANCER RECURRENT ( 10 patients )
CHRONIC LYMPHOCYTIC LEUKAEMIA TRANSFORMATION ( 10 patients )
OVARIAN GERM CELL CANCER ( 9 patients )
ALLERGIC GRANULOMATOUS ANGIITIS ( 9 patients )
T-CELL LYMPHOMA REFRACTORY ( 9 patients )
LUNG NEOPLASM MALIGNANT ( 9 patients )
RETINOBLASTOMA BILATERAL ( 9 patients )
GOODPASTURE'S SYNDROME ( 9 patients )
BRAIN NEOPLASM ( 9 patients )
SJOGREN'S SYNDROME ( 9 patients )
BURKITT'S LYMPHOMA STAGE III ( 9 patients )
DISEASE PROGRESSION ( 9 patients )
PEMPHIGOID ( 8 patients )
PINEALOBLASTOMA ( 8 patients )
RETINAL VASCULITIS ( 8 patients )
ADJUVANT THERAPY ( 8 patients )
DIFFUSE LARGE B-CELL LYMPHOMA STAGE III ( 8 patients )
HIGH GRADE B-CELL LYMPHOMA BURKITT-LIKE LYMPHOMA ( 8 patients )
POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER ( 8 patients )
PRECURSOR B-LYMPHOBLASTIC LYMPHOMA ( 8 patients )
TEMPORAL ARTERITIS ( 8 patients )
ANAPLASTIC ASTROCYTOMA ( 8 patients )
BREAST NEOPLASM ( 8 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 8 patients )
LEUKAEMIA PLASMACYTIC ( 8 patients )
HAEMATOLOGICAL MALIGNANCY ( 8 patients )
RENAL CELL CARCINOMA ( 8 patients )
CRYOGLOBULINAEMIA ( 8 patients )
METASTASIS ( 8 patients )
FOETAL EXPOSURE TIMING UNSPECIFIED ( 8 patients )
MANTLE CELL LYMPHOMA STAGE IV ( 8 patients )
COLON CANCER ( 8 patients )
FOLLICLE CENTRE LYMPHOMA, FOLLICULAR GRADE I, II, III ( 8 patients )
THYMOMA ( 7 patients )
LYMPHANGIOMA ( 7 patients )
METASTASES TO MENINGES ( 7 patients )
TRANSPLANT EVALUATION ( 7 patients )
MANTLE CELL LYMPHOMA RECURRENT ( 7 patients )
ACUTE BIPHENOTYPIC LEUKAEMIA ( 7 patients )
ALVEOLITIS ( 7 patients )
SARCOMA METASTATIC ( 7 patients )
ACUTE PROMYELOCYTIC LEUKAEMIA ( 7 patients )
FIBROSARCOMA ( 7 patients )
SYSTEMIC SCLEROSIS ( 7 patients )
FOCAL SEGMENTAL GLOMERULOSCLEROSIS ( 7 patients )
MANTLE CELL LYMPHOMA REFRACTORY ( 7 patients )
LYMPHOPLASMACYTOID LYMPHOMA/IMMUNOCYTOMA ( 7 patients )
T-CELL LYMPHOMA STAGE III ( 7 patients )
BREAST CANCER STAGE I ( 6 patients )
EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE ( 6 patients )
ANTISYNTHETASE SYNDROME ( 6 patients )
MALIGNANT HISTIOCYTOSIS ( 6 patients )
CONJUNCTIVITIS ( 6 patients )
PRIMARY IMMUNODEFICIENCY SYNDROME ( 6 patients )

Drugs with high FDA adverse event association with myopathy:

LIPITOR (517 patients)
ZOCOR (480 patients)
ASPIRIN (474 patients)
SIMVASTATIN (410 patients)
FOSAMAX (309 patients)
PREDNISONE (241 patients)
CRESTOR (239 patients)
ZOMETA (201 patients)
PREDNISOLONE (199 patients)
LASIX (177 patients)
FUROSEMIDE (162 patients)
ZETIA (153 patients)
HYDROCHLOROTHIAZIDE (144 patients)
PREDNISONE TAB (139 patients)
LEVOTHYROXINE SODIUM (138 patients)
VIOXX (130 patients)
ALLOPURINOL (125 patients)
DEXAMETHASONE (124 patients)
INSULIN (120 patients)
COUMADIN (118 patients)
CYCLOSPORINE (113 patients)
ATENOLOL (112 patients)
ATORVASTATIN CALCIUM (110 patients)
NORVASC (108 patients)
CLARITHROMYCIN (107 patients)
AMBIEN (104 patients)
MYCOPHENOLATE MOFETIL (103 patients)
LISINOPRIL (99 patients)
NOROXIN (98 patients)
DECADRON (97 patients)
OMEPRAZOLE (97 patients)
POTASSIUM CHLORIDE (96 patients)
SORAFENIB (RAF KINASE INHIBITOR) (95 patients)
GABAPENTIN (94 patients)
SYNTHROID (94 patients)
LAMIVUDINE (90 patients)
AMLODIPINE (90 patients)
RAMIPRIL (89 patients)
NEXIUM (88 patients)
PRILOSEC (87 patients)
METHYLPREDNISOLONE (85 patients)
WARFARIN SODIUM (83 patients)
ZIDOVUDINE (82 patients)
ALBUTEROL (82 patients)
LANSOPRAZOLE (80 patients)
MEK INHIBITOR (DIHYDROXYPROP-DIFLU-METHOXYPHEN-CYCLOPROPA-SULFAMI) (80 patients)
PROTONIX (79 patients)
ACETAMINOPHEN (77 patients)
FOLIC ACID (77 patients)
MULTI-VITAMINS (75 patients)
XANAX (75 patients)
COZAAR (73 patients)
NEURONTIN (73 patients)
REMICADE (71 patients)
REVLIMID (69 patients)
HUMIRA (68 patients)
AMIODARONE HCL (67 patients)
FLONASE (65 patients)
CELEXA (64 patients)
FERROUS SULFATE TAB (64 patients)
ATORVASTATIN (64 patients)
AMLODIPINE BESYLATE (64 patients)
SPIRONOLACTONE (63 patients)
MAGNEVIST (62 patients)
VYTORIN (62 patients)
ZOLOFT (61 patients)
PEPCID (60 patients)
PROGRAF (60 patients)
CITALOPRAM HYDROBROMIDE (59 patients)
VICODIN (59 patients)
ADVAIR DISKUS 100/50 (59 patients)
ULTRAVIST 150 (59 patients)
PLAVIX (59 patients)
METHOTREXATE (58 patients)
COLCHICINE (58 patients)
AREDIA (57 patients)
OXYCONTIN (57 patients)
LYRICA (57 patients)
DIDANOSINE (56 patients)
ENALAPRIL MALEATE (55 patients)
HEPARIN SODIUM INJECTION (55 patients)
TAMOXIFEN CITRATE (55 patients)
ACYCLOVIR (52 patients)
FENOFIBRATE (52 patients)
PRAVASTATIN (52 patients)
CLONAZEPAM (51 patients)
ITRACONAZOLE (51 patients)
CYCLOPHOSPHAMIDE (51 patients)
DIGOXIN (49 patients)
SEBIVO (49 patients)
TOPROL-XL (49 patients)
LORAZEPAM (48 patients)
DILTIAZEM (48 patients)
LORTAB (48 patients)
ELAVIL (47 patients)
DIFLUCAN (47 patients)
METOPROLOL TARTRATE (46 patients)
ATIVAN (46 patients)
VELCADE (45 patients)
ALENDRONATE SODIUM (45 patients)
VITAMIN D (45 patients)
KLOR-CON (45 patients)
PRAVACHOL (45 patients)
WELLBUTRIN (44 patients)
TRICOR (44 patients)
DARVOCET-N 100 (44 patients)
PERCOCET (44 patients)
RAPAMUNE (43 patients)
ASCORBIC ACID (43 patients)
LEVAQUIN (43 patients)
AROMASIN (43 patients)
DIAZEPAM (43 patients)
ZANTAC (43 patients)
GEMFIBROZIL (41 patients)
CELEBREX (41 patients)
OXYCODONE HCL (41 patients)
ABACAVIR (40 patients)
LEXAPRO (40 patients)
NIFEDIPINE (40 patients)
RADIATION THERAPY (39 patients)
ACETYLSALICYLIC ACID SRT (39 patients)
ACIPHEX (39 patients)
METFORMIN HCL (39 patients)
IRON (39 patients)
ALTACE (39 patients)
TACROLIMUS (38 patients)
EFAVIRENZ (38 patients)
ZYPREXA (38 patients)
ZYRTEC (38 patients)
LESCOL (37 patients)
[THERAPY UNSPECIFIED] (37 patients)
METOPROLOL (37 patients)
GLEEVEC (37 patients)
PANTOPRAZOLE SODIUM (36 patients)
FOSAMAX PLUS D (36 patients)
PROPRANOLOL HYDROCHLORIDE (36 patients)
EFFEXOR (36 patients)
AMIODARONE (36 patients)
CEFTRIAXONE (36 patients)
HERCEPTIN (35 patients)
THALIDOMIDE (35 patients)
FUSIDIC ACID (35 patients)
SINGULAIR (35 patients)
IBUPROFEN (35 patients)
SPIRIVA (35 patients)
LOSARTAN POTASSIUM (35 patients)
VANCOMYCIN (35 patients)
WARFARIN (34 patients)
PERIDEX (34 patients)
BISOPROLOL (34 patients)
HYZAAR (34 patients)
SIROLIMUS (34 patients)
SOLU-MEDROL (34 patients)
ALPRAZOLAM (34 patients)
CO-TRIMOXAZOLE (34 patients)
AMITRIPTYLINE HCL (34 patients)
COREG (34 patients)
VITAMINS (UNSPECIFIED) (33 patients)
ACETYLSALICYLIC ACID (33 patients)
AZATHIOPRINE (33 patients)
ZOFRAN (33 patients)
CALTRATE +D (33 patients)
PROTEINASE INHIBITORS (33 patients)
CARTIA /USA/ (33 patients)
NIASPAN (33 patients)
PANTOPRAZOLE (33 patients)
MEGESTROL ACETATE (32 patients)
COMPAZINE (32 patients)
ADENOSINE (32 patients)
ALDACTONE (32 patients)
LANTUS (32 patients)
GASMOTIN (32 patients)
PROZAC (32 patients)
ARIMIDEX (31 patients)
AVELOX (31 patients)
FENTANYL (31 patients)
CALCIUM (UNSPECIFIED) (31 patients)
PAXIL (31 patients)
GLIPIZIDE (31 patients)
FLUCONAZOLE (31 patients)
ARANESP (31 patients)
CLARITIN (31 patients)
DILAUDID (31 patients)
NEUPOGEN (31 patients)
AVANDIA (31 patients)
B12 ^RECIP^ (30 patients)
K-DUR (30 patients)
CALCIUM CARBONATE (30 patients)
CELLCEPT (30 patients)
METFORMIN (30 patients)
CLOPIDOGREL (30 patients)
TRAMADOL HCL (30 patients)
REQUIP (29 patients)
CARVEDILOL (29 patients)
GLUCOPHAGE (29 patients)
FLOMAX (29 patients)
ZESTRIL (29 patients)
MIRTAZAPINE (29 patients)
TIAZAC (29 patients)
CAPECITABINE (29 patients)
KETEK (29 patients)
NICORANDIL (29 patients)
VERAPAMIL (29 patients)
CYMBALTA (28 patients)
RALTEGRAVIR (28 patients)
LOVASTATIN (28 patients)
CALCIUM (28 patients)
ACTOS (28 patients)
MICARDIS (28 patients)
DILTIAZEM HYDROCHLORIDE (28 patients)

Most common side effects for patients taking CYCLOPHOSPHAMIDE:

FEBRILE NEUTROPENIA (4212 patients)
NEUTROPENIA (2894 patients)
PYREXIA (2893 patients)
PNEUMONIA (1880 patients)
DIARRHOEA (1702 patients)
SEPSIS (1670 patients)
NAUSEA (1576 patients)
THROMBOCYTOPENIA (1515 patients)
ANAEMIA (1499 patients)
DYSPNOEA (1444 patients)
INFECTION (1434 patients)
VOMITING (1385 patients)
WHITE BLOOD CELL COUNT DECREASED (1215 patients)
PANCYTOPENIA (1178 patients)
MUCOSAL INFLAMMATION (1076 patients)
HYPOTENSION (1067 patients)
DEATH (1035 patients)
PLATELET COUNT DECREASED (1028 patients)
FATIGUE (1006 patients)
RESPIRATORY FAILURE (1006 patients)
LEUKOPENIA (927 patients)
HAEMOGLOBIN DECREASED (927 patients)
RENAL FAILURE (872 patients)
PLEURAL EFFUSION (872 patients)
DRUG INEFFECTIVE (851 patients)
MULTI-ORGAN FAILURE (834 patients)
SEPTIC SHOCK (813 patients)
ASTHENIA (782 patients)
ABDOMINAL PAIN (768 patients)
DEHYDRATION (756 patients)
MYELODYSPLASTIC SYNDROME (753 patients)
PAIN (719 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (712 patients)
GRAFT VERSUS HOST DISEASE (709 patients)
PULMONARY EMBOLISM (703 patients)
HEADACHE (698 patients)
DISEASE PROGRESSION (697 patients)
CYTOMEGALOVIRUS INFECTION (695 patients)
ACUTE MYELOID LEUKAEMIA (671 patients)
RENAL FAILURE ACUTE (670 patients)
NEUTROPHIL COUNT DECREASED (661 patients)
PNEUMOCYSTIS JIROVECI PNEUMONIA (624 patients)
OSTEONECROSIS (622 patients)
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (594 patients)
INTERSTITIAL LUNG DISEASE (591 patients)
COUGH (574 patients)
RASH (570 patients)
BONE MARROW FAILURE (568 patients)
ALANINE AMINOTRANSFERASE INCREASED (554 patients)
CARDIAC FAILURE (546 patients)
MALAISE (541 patients)
STOMATITIS (531 patients)
WEIGHT DECREASED (530 patients)
CONVULSION (522 patients)
ACUTE GRAFT VERSUS HOST DISEASE (518 patients)
HYPERTENSION (502 patients)
HERPES ZOSTER (490 patients)
NEUROPATHY PERIPHERAL (485 patients)
BACK PAIN (478 patients)
ACUTE RESPIRATORY DISTRESS SYNDROME (475 patients)
TACHYCARDIA (474 patients)
DEEP VEIN THROMBOSIS (473 patients)
NEUTROPENIC SEPSIS (473 patients)
CHILLS (472 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (468 patients)
ARTHRALGIA (449 patients)
MALIGNANT NEOPLASM PROGRESSION (448 patients)
CHEST PAIN (447 patients)
CONSTIPATION (442 patients)
ATRIAL FIBRILLATION (433 patients)
DIZZINESS (431 patients)
HYPOKALAEMIA (427 patients)
HYPOXIA (426 patients)
ASCITES (418 patients)
PAIN IN EXTREMITY (415 patients)
RENAL IMPAIRMENT (414 patients)
STAPHYLOCOCCAL INFECTION (412 patients)
HEPATIC FAILURE (412 patients)
OEDEMA PERIPHERAL (410 patients)
BLOOD BILIRUBIN INCREASED (408 patients)
STEM CELL TRANSPLANT (406 patients)
DRUG EXPOSURE DURING PREGNANCY (398 patients)
CARDIAC FAILURE CONGESTIVE (397 patients)
CONFUSIONAL STATE (395 patients)
HEPATITIS B (395 patients)
SYNCOPE (383 patients)
DRUG TOXICITY (383 patients)
BLOOD CREATININE INCREASED (383 patients)
VENOOCCLUSIVE LIVER DISEASE (379 patients)
URINARY TRACT INFECTION (377 patients)
CHRONIC GRAFT VERSUS HOST DISEASE (375 patients)
LYMPHOPENIA (371 patients)
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN (368 patients)
CONDITION AGGRAVATED (367 patients)
CARDIAC ARREST (359 patients)
BONE PAIN (356 patients)
LUNG INFILTRATION (350 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (348 patients)
OEDEMA (347 patients)
CYSTITIS HAEMORRHAGIC (338 patients)
DECREASED APPETITE (335 patients)
PULMONARY OEDEMA (334 patients)
PNEUMONITIS (329 patients)
LIVER DISORDER (328 patients)
PARAESTHESIA (328 patients)
GASTROINTESTINAL HAEMORRHAGE (326 patients)
ERYTHEMA (319 patients)
CELLULITIS (319 patients)
LYMPHADENOPATHY (317 patients)
RESPIRATORY DISTRESS (315 patients)
DRUG INTERACTION (311 patients)
DEPRESSION (297 patients)
TOXICITY TO VARIOUS AGENTS (293 patients)
TUMOUR LYSIS SYNDROME (290 patients)
HEPATIC FUNCTION ABNORMAL (288 patients)
EJECTION FRACTION DECREASED (288 patients)
NEOPLASM MALIGNANT (286 patients)
ANXIETY (285 patients)
HYPONATRAEMIA (285 patients)
MYALGIA (284 patients)
HAEMATOCRIT DECREASED (284 patients)
CARDIOMYOPATHY (282 patients)
AGRANULOCYTOSIS (282 patients)
FALL (278 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (276 patients)
MUSCULAR WEAKNESS (276 patients)
MYOCARDIAL INFARCTION (272 patients)
DYSPHAGIA (271 patients)
FUNGAL INFECTION (270 patients)
THROMBOTIC MICROANGIOPATHY (264 patients)
LUNG DISORDER (258 patients)
HISTIOCYTOSIS HAEMATOPHAGIC (257 patients)
HEPATOTOXICITY (255 patients)
MULTIPLE MYELOMA (255 patients)
HAEMATURIA (253 patients)
NEUROTOXICITY (248 patients)
ATELECTASIS (247 patients)
CEREBRAL HAEMORRHAGE (247 patients)
ORAL CANDIDIASIS (244 patients)
CARDIO-RESPIRATORY ARREST (243 patients)
LOSS OF CONSCIOUSNESS (240 patients)
HYPERGLYCAEMIA (238 patients)
C-REACTIVE PROTEIN INCREASED (238 patients)
ANOREXIA (237 patients)
PRURITUS (237 patients)
ALOPECIA (235 patients)
EPSTEIN-BARR VIRUS INFECTION (234 patients)
VENOOCCLUSIVE DISEASE (233 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (233 patients)
HYPERSENSITIVITY (232 patients)
HYPOAESTHESIA (231 patients)
COLITIS (231 patients)
CANDIDIASIS (230 patients)
LUNG INFECTION (228 patients)
EPSTEIN-BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISORDER (227 patients)
THROMBOSIS (226 patients)
DISEASE RECURRENCE (226 patients)
PERICARDIAL EFFUSION (225 patients)
EPISTAXIS (224 patients)
OSTEONECROSIS OF JAW (222 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (221 patients)
SINUSITIS (218 patients)
HEPATITIS (215 patients)
WEIGHT INCREASED (212 patients)
ASPERGILLOSIS (212 patients)
BACTERAEMIA (212 patients)
TREMOR (210 patients)
LYMPHOMA (210 patients)
HAEMORRHAGE (209 patients)
PULMONARY FIBROSIS (209 patients)
BACTERIAL INFECTION (208 patients)
OSTEOMYELITIS (208 patients)
OXYGEN SATURATION DECREASED (207 patients)
BRONCHOPULMONARY ASPERGILLOSIS (204 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (202 patients)
BONE DISORDER (201 patients)
ABDOMINAL PAIN UPPER (200 patients)
SOMNOLENCE (200 patients)
FEBRILE BONE MARROW APLASIA (200 patients)
PAIN IN JAW (197 patients)
ABDOMINAL DISTENSION (194 patients)
CEREBROVASCULAR ACCIDENT (193 patients)
HEART RATE INCREASED (192 patients)
BLOOD CULTURE POSITIVE (192 patients)
ENCEPHALOPATHY (188 patients)
NERVOUS SYSTEM DISORDER (187 patients)
HYPERBILIRUBINAEMIA (185 patients)
HAEMATOTOXICITY (184 patients)
WHITE BLOOD CELL COUNT INCREASED (184 patients)
COMA (184 patients)
HYPOCALCAEMIA (184 patients)
BLOOD PRESSURE DECREASED (182 patients)
PULMONARY HAEMORRHAGE (181 patients)
PERIPHERAL SENSORY NEUROPATHY (180 patients)
LEUKOENCEPHALOPATHY (180 patients)
DIFFUSE LARGE B-CELL LYMPHOMA (180 patients)
STAPHYLOCOCCAL SEPSIS (180 patients)
PSEUDOMONAS INFECTION (180 patients)
HAEMODIALYSIS (176 patients)
APLASIA (176 patients)
LEFT VENTRICULAR DYSFUNCTION (176 patients)
LEUKOCYTOSIS (175 patients)
BODY TEMPERATURE INCREASED (174 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (172 patients)
ACUTE GRAFT VERSUS HOST DISEASE IN INTESTINE (172 patients)
PANCREATITIS (172 patients)
PNEUMOTHORAX (172 patients)
INSOMNIA (171 patients)
RESPIRATORY DISORDER (169 patients)
GASTRITIS (168 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for CYCLOPHOSPHAMIDE

Issue	Description / Topic	Timestamp
QUESTION SINUS TACHYCARDIA	CH-AS SOON AS I STARTED CYCLOPHOSPHAMIDE AT LEAST WITHIN A WEEK I NOTICED SINUS TACHYCARDIA. I WAS UP AND ABOUT DOING MY ROUTINE CARE AND FELT WINDED....I WAS ALSO ON AVASTIN EVERY 2 WKS DRIP INFUSION. AVASTIN CAUSED HTN FOR ME. WHICH I HAVE NEVER EVER HAD NOR SINUS TACH. AND THIS WAS A NEW TREATMENT. AFTER MANY AS I HAVE STAGE IV PERITONEAL CANCER/OVARIAN CA, IN WHICH I FOUND SINCE IM AN ULTRASOUND TECH. THESE TWO COMBINATIONS HAVE BEEN BRUTLE THE WORST. AND IVE BEEN ON ALOT OF CHEMO AND CHEMO COMBINATIONS. NEVER HAVE I FELT SO MISERABLE WITH THIS COMBINATION. RIGHT NOW IM OFF AVASTIN CAUSE I EXPERIENCED A GI BLEED OF SOME SORT HAD TO WAIT TO GET MY COLONOSCOPY, WHICH TOOK ALMOST A MONTH TO SCHEDULE. NOW IVE RELAPSED SINCE IN THIS MEANING MY CA125 WAS JUST DOWN TO 200 ......MY COLONCOSCOPY WAS NORMAL. I TOLD BY THE NURSE OR PA AND SAID THIS DRUG'S SIDE EFFECT IS NOT S.TACH. AND I WAS SEEING IT OVER THE INTERNET. MY HOLTER MONITOR PROVED I WAS IN S.T. BUT WHEN RESTING MY HEART RATE GOES TO NORMAL..BUT AS I GET UP AND AROUND ITS INCREASES. I UNDERSTAND AS YOU GO DOWN THE LIST OF DRUGS USED IT NARROWS THE CHEMO OPPORTUNITIES TO STAY ALIVE.	2015-06-08 10:22:15
QUESTION EXOPHTHALMOS	My sister has multiple myeloma .lots of spine tumours. Had four doses of velcade and one of cyclophosphamide. She has developed bulging eye.(Right). Also double vision. Her disease is quite advanced. Could it be due to a lesion on brain or chemo drugs?	2015-07-04 06:09:53
QUESTION TESTICULAR PAIN	pls can cyclophosphamide drug cause testes pain	2015-09-12 02:15:48
QUESTION TESTICULAR PAIN	pls can cyclophosphamide drug cause testes pain	2015-09-12 02:16:08

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about myopathy and CYCLOPHOSPHAMIDE, post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking CYCLOPHOSPHAMIDE, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in CYCLOPHOSPHAMIDE. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for CYCLOPHOSPHAMIDE experts. If you are a healthcare provider experienced in prescribing CYCLOPHOSPHAMIDE, please register here.